ArticleProgres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie2022
Tolerance and efficacy of platelet-rich plasma injections in Peyronie's disease: Pilot study.
Article in Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Efficacy of platelet-rich plasma in the treatment of erectile dysfunction: A meta-analysis of controlled and single-arm trials.PloS one · 2024Pooled it
- A phase 2 randomized, placebo-controlled crossover trial to evaluate safety and efficacy of platelet-rich plasma injections for Peyronie's disease: clinical trial update.International journal of impotence research · 2024Trial
- Platelet-rich plasma in selected urological conditions: a narrative review of biological rationale, current evidence, and limitations.Translational andrology and urology · 2026Review
- Intralesional Platelet-Rich Plasma for Treating Chronic Peyronie's Disease: A Single-Center Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- A novel approach to Peyronie's disease: Intralesional injection of lyophilized platelet-derived growth factors.Central European journal of urology · 2026Article
- Platelet-rich plasma intra-plaque injections rapidly reduce penile curvature and improve sexual function in Peyronie's disease patients: results from a prospective large-cohort study.World journal of urology · 2025Article
- Review
- Review
- Acute Phase Peyronie's Disease: Where Do We Stand?Cureus · 2024Review
- Identifying hub genes, key pathways and key immune-related genes in Peyronie's disease by integrated bioinformatic analysis.Frontiers in pharmacology · 2022Article
- Evidence of restorative therapies in the treatment of Peyronie disease: A narrative review.International braz j urol : official journal of the Brazilian Society of UrologyReview
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPlatelet-rich plasma (PRP) injections are increasingly proposed for the treatment of Peyronie's disease since the discontinuation of Xiapex® despite poorly understood results.
objectivesEvaluation of the tolerance and efficacy of intra-plate PRP injections in patients with Peyronie's disease.
methodsThree intra-plate injections of PRP were performed 15 days apart in 17 patients with Peyronie's disease. The Peyronie's Disease Questionnaire (PDQ) and the measurement of the angle of curvature of the erect penis were assessed before treatment and then 1, 3 and 6 months after treatment. Erectile function was assessed by different questionnaires (IIEF-EF, EHS, SEP, sexual discomfort score).
resultsNo side effects were noted during the study period. Three months after treatment, all three PDQ domains were significantly improved (P=0.002; P=0.015; P=0.017 respectively). The angle of curvature of the penis was significantly decreased by 11.8° with a mean angle of 40.4° before treatment and 28.6° after (P=0.007). The IIEF-EF score was significantly improved after treatment (mean preoperative value: 10.67) with a gain of 5 points at months 1 and 6 (P=0.01 and P=0.036 respectively) and 7 points at month 3 (P=0.04).
conclusionOur initial experience suggests that PRP injections for Peyronie's disease are safe. Although the limited data is suggestive of efficacy, a placebo control will be required for confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.